Tango Therapeutics, Inc. (TNGX): Price and Financial Metrics
GET POWR RATINGS... FREE!
TNGX Stock Price Chart Interactive Chart >
TNGX Price/Volume Stats
| Current price | $6.22 | 52-week high | $18.84 |
| Prev. close | $5.88 | 52-week low | $4.41 |
| Day low | $5.80 | Volume | 252,400 |
| Day high | $6.22 | Avg. volume | 224,134 |
| 50-day MA | $6.80 | Dividend yield | N/A |
| 200-day MA | $10.13 | Market Cap | 546.72M |
Tango Therapeutics, Inc. (TNGX) Company Bio
Tango Therapeutics, Inc., a biotechnology company, discovers and develops medicines for the treatment of cancer. Its lead program is TNG908, a protein arginine methyl transferase 5 inhibitor that is being developed as a treatment for cancers with MTAP deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor that treats cancers with BRCA1 mutations. Tango Therapeutics, Inc. has strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
Latest TNGX News From Around the Web
Below are the latest news stories about Tango Therapeutics Inc that investors may wish to consider to help them evaluate TNGX as an investment opportunity.
Tango Therapeutics to Participate in Upcoming Investor ConferencesCAMBRIDGE, Mass., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that members of the management team are scheduled to participate in the following upcoming virtual investor conferences in February: Guggenheim 2022 Oncology Conference Date: Wednesday, February 9, 2022Time: 9:00 AM ET 11th Annual SVB Leerink Global Healthcare ConferenceDate: |
Tango Therapeutics Announces Clearance of TNG908 IND by FDA and Recent Pipeline Progress Updates- TNG908 IND cleared by FDA, Phase 1/2 trial expected to start in 1H 2022 - Additional pipeline programs progressing throughout 2022 CAMBRIDGE, Mass., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced progress updates across its pipeline and recent corporate highlights. “Last year we achieved a critical milestone, becoming a publicly-traded c |
We're Interested To See How Tango Therapeutics (NASDAQ:TNGX) Uses Its Cash Hoard To GrowJust because a business does not make any money, does not mean that the stock will go down. For example, although... |
Boxer Capital, Llc Buys Tyra Biosciences Inc, Tango Therapeutics Inc, Blueprint Medicines Corp, ...Investment company Boxer Capital, Llc (Current Portfolio) buys Tyra Biosciences Inc, Tango Therapeutics Inc, Blueprint Medicines Corp, Fulcrum Therapeutics Inc, Turning Point Therapeutics Inc, sells Seagen Inc, Amarin Corp PLC, Therapeutics Acquisition Corp, , Agenus Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Boxer Capital, Llc. |
Tango Therapeutics to Participate in the Jefferies London Healthcare ConferenceCAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that members of the management team are scheduled to participate in the the Jefferies London Healthcare Conference. The presentation will be available on-demand starting at 8 AM GMT on Thursday, November 18, 2021. A webcast of the event will be available under the "Events & P |
TNGX Price Returns
| 1-mo | -15.83% |
| 3-mo | -30.73% |
| 6-mo | -37.74% |
| 1-year | -44.46% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -43.14% |
| 2021 | -4.37% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...